A Double-blind, Placebo-controlled, Randomized Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics After Single or Repeat Twice-daily Doses of AP02, a Nebulized Formulation of Nintedanib

Michelle Palacios, Rebecca Boone, Stephen Pham, Howard M. Lazarus, Craig S. Conoscenti, Melissa Rhodes